NCT05923944 Video Game Play to Alleviate Adolescent Anxiety
| NCT ID | NCT05923944 |
| Status | Recruiting |
| Phase | — |
| Sponsor | School of Health Sciences Geneva |
| Condition | Anxiety |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2024-06-01 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Adolescence is a critical period for the onset and maintenance of anxiety disorders, which raises the importance of intervening early; one possibility of doing so is via digital interventions. At least two lines of research have been explored in the past years in this area. First, studies have tested the anxiolytic effects of casual video games, hypothesizing that, through the induction of flow, these games can effectively distract individuals from anxiety-related thoughts and feelings. Second, the bidirectional link between poor attentional control and higher anxiety has led to the design of novel interventions aiming to improve attentional control such as working memory training studies. Importantly, action video games, classified as a distinct gaming genre, have been shown to enhance attentional control. In this study, we aim to compare the effects of action video game play and casual game play to a no-training group, assessing their potential to alleviate anxiety when delivered entirely online. The goal of this three- arms randomized controlled trial is to evaluate the feasibility of a 6-week video game training intervention to reduce adolescent anxiety-related symptoms. We will also examine the efficacy of the proposed treatment when entirely deployed at adolescents' home.
Eligibility Criteria
Inclusion Criteria: 1. Adolescents aged 11-15 years 2. Elevated anxiety symptoms, defined as a total score of ≥15 on the 41-item parent-report version of the Screen for Child Anxiety Related Emotional Disorders (SCARED). 3. Access to a computer (at least Windows 7 or Mac OSX) at home and a reliable internet connection Exclusion Criteria: 1. DSM diagnoses of Bipolar, Psychosis, Autism Spectrum Disorder, present or past. 2. Neurological injury (i.e. head injury) 3. Currently enrolled in another cognitive training intervention
Contact & Investigator
Daphné Bavelier, Professor
PRINCIPAL INVESTIGATOR
University of Geneva, Switzerland
Frequently Asked Questions
Who can join the NCT05923944 clinical trial?
This trial is open to participants of all sexes, aged 11 Years or older, up to 15 Years, studying Anxiety. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05923944 currently recruiting?
Yes, NCT05923944 is actively recruiting participants. Contact the research team at naima.gradi@unige.ch for enrollment information.
Where is the NCT05923944 trial being conducted?
This trial is being conducted at Miami, United States, Haifa, Israel, Geneva, Switzerland.
Who is sponsoring the NCT05923944 clinical trial?
NCT05923944 is sponsored by School of Health Sciences Geneva. The principal investigator is Daphné Bavelier, Professor at University of Geneva, Switzerland. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.